FOXO3 and breast carcinoma: The compound CDRI-85/287 decreased the expression of phosphorylated FOXO-3a in both MDA-MB 231 and primary breast cancer cells in contrast to EGF which in turn prevented its proteasomal degradation leading to increased expression of FOXO-3a protein confirmed by immunoblotting studies (Fig. 5).